Selecta Biosciences (NASDAQ:SELB) released its quarterly earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.10), MarketWatch Earnings reports.
Shares of Selecta Biosciences stock traded up $0.05 on Friday, reaching $2.98. 824,913 shares of the company were exchanged, compared to its average volume of 1,621,164. Selecta Biosciences has a fifty-two week low of $1.47 and a fifty-two week high of $5.70. The firm has a market capitalization of $337.32 million, a price-to-earnings ratio of -3.59 and a beta of 1.18. The stock has a fifty day moving average price of $3.79 and a 200-day moving average price of $3.71.
A number of research firms recently commented on SELB. William Blair upgraded shares of Selecta Biosciences from a “market perform” rating to an “outperform” rating in a research note on Thursday, March 18th. Zacks Investment Research cut Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 9th. HC Wainwright restated a “buy” rating on shares of Selecta Biosciences in a report on Monday, May 3rd. Finally, Mizuho raised Selecta Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $2.50 to $8.00 in a report on Tuesday, January 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $7.20.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses.
Recommended Story: Consumer Price Index (CPI)
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.